AdvaMed, the world’s leading medtech trade association, communicated to Centers for Medicaid & Medicare Services (CMS) recommendations regarding administration of the Open Payments program.

AdvaMed, the Medtech Association, asked the United States Court of Appeals to support a fair and balanced approach to patent damages.

The AdvaMed Code of Ethics on Interactions with Health Care Professionals in China – the “AdvaMed China Code” or “Code” – serves as a foundational charter for medical technology companies’ compliance programs and encourages the companies to adopt best practices in the ethics unique to their industry.  

In a decisive victory for medtech innovation, the D.C. Circuit Court of Appeals earlier this month held that the Digital Millennium Copyright Act (DMCA) regulations are judicially reviewable. Under this ruling, the Library of Congress must rein in rulemaking that inadvertently could jeopardize patient safety and give away intellectual property by helping unregulated, third-party repair companies hack into highly complex, lifesaving medical devices. Instead, this decision ensures that exemptions to the DMCA anticircumvention provision are subject to the bedrock principle of judicial review. 

Today, The Advanced Medical Technology Association (AdvaMed) commended the U.S. Court of Appeals for the District of Columbia Circuit’s decision in the case Medical Imaging & Technology Alliance and Advanced Medical Technology Association v. Library of Congress and Carla Hayden (Case No. 23-5067), which ruled favorably in AdvaMed’s lawsuit to prevent unauthorized and unregulated repair companies from hacking into life-saving medical devices.

The Supreme Court will soon address the fate of agency deference—an issue presented in Relentless v. Department of Commerce and Loper Bright Enterprises v. Raimondo—in a ruling expected to have far-reaching effects on how federal agencies regulate medtech and many other industries and how the industries interact with lawmakers, agencies, and the courts.

Third party litigation funding has become widespread in the civil justice system. The growing use of TPLF to generate mass tort litigation, particularly against manufacturers of medical technology, misuses the civil justice system, adversely affects public health, chills innovation, and harms patients.

Hear from AdvaMed’s data privacy expert, Terry Chang, on the critical exemptions we seek in comprehensive data privacy laws across the country.

AdvaMed’s digital health policy expert, Geeta Pamidimukkala, and payment and health care delivery policy expert, Kirsten Tullia, break down how artificial intelligence and machine learning (AI/ML) technologies are transforming patient care and the FDA’s crucial role in overseeing AI-powered medical devices.

Jones Lang Lasalle Inc. is the trusted real estate advisor to over 100 AdvaMed members across the globe and will be presenting the tools and strategies they have employed to achieve facility savings and mitigate risk within this very dynamic real estate market.

AdvaMed, the Medtech Association, commended the House of Representatives’ bipartisan Task Force on Artificial Intelligence for urging the Centers for Medicare & Medicaid Services (CMS) to develop a formalized payment pathway for AI-enabled medical devices. AI-enabled medical devices are FDA-cleared and produce clinical information to aid in patient diagnosis or treatment.

Join Porzio in this session that will help med device compliance leaders with messaging, designing, and implementing risk assessments, a key component of an effective healthcare compliance program.

This white paper explores the evolution of current biopharmaceutical commercial models. By addressing key considerations essential for every healthcare leader, this shares the impact of integrating
digital assets clinician engagement
and enhancing health outcomes.

The industry is at the forefront of physical and digital technologies, with implications for research, development, manufacturing and patient care. Digital technologies and workflows can unlock discoveries, leading
to new markets, opportunities and better outcomes.

Join King & Spalding for this engaging panel that will cover common experiences and practical considerations for advising medical device company executives during a government investigation.